Key Points
- Agios insider Sarah Gheuens sold 30,000 shares at an average price of $30.48, worth $914,400, reducing her stake by 35.44% to 54,645 shares. The transaction was made under a pre-arranged Rule 10b5-1 trading plan.
- Agios recently reported a quarterly loss of $1.69 per share, missing estimates by $0.04, although revenue of $44.75 million exceeded analyst expectations of $26.39 million.
- Analyst sentiment is mixed but leans positive: five analysts rate AGIO a Buy, four rate it Hold and one rates it Sell, with an average price target of $40.88 versus a recent share price of $31.95.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the sale, the insider owned 54,645 shares in the company, valued at $1,665,579.60. This represents a 35.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Agios Pharmaceuticals Stock Up 0.7%
AGIO opened at $31.95 on Friday. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00. The business has a 50 day moving average of $34.69 and a 200-day moving average of $31.00. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -4.56 and a beta of 0.58.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts' consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. As a group, analysts expect that Agios Pharmaceuticals, Inc. will post -6.12 earnings per share for the current year.
Wall Street Analysts Forecast Growth
AGIO has been the topic of several research analyst reports. Citigroup increased their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Bank of America lifted their target price on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 7th. Royal Bank Of Canada upped their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a "sector perform" rating in a research note on Tuesday, July 7th. Truist Financial lowered their price target on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating on the stock in a report on Friday, July 31st. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $40.88.
Get Our Latest Report on Agios Pharmaceuticals
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Creative Planning lifted its holdings in Agios Pharmaceuticals by 2.2% in the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company's stock valued at $527,000 after buying an additional 280 shares during the period. Assetmark Inc. grew its holdings in Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 362 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Agios Pharmaceuticals by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company's stock worth $4,393,000 after acquiring an additional 512 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Agios Pharmaceuticals by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company's stock worth $77,000 after acquiring an additional 588 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its position in shares of Agios Pharmaceuticals by 3.4% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company's stock worth $796,000 after acquiring an additional 662 shares in the last quarter.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
